Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309562 | 0.83 | MAPT (0.71) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL11273206 | 0.83 | MAPT (0.71) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL2563368 | 0.83 | CYP1A2 (0.71) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL2556427 | 0.82 | MAPT (0.69) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL1002660 | 0.81 | MAPT (0.68) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL29708058 | 0.81 | MAPT (0.68) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL16307957 | 0.81 | MAPT (0.68) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL15330210 | 0.80 | MAPT (0.66) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL22219381 | 0.80 | MAPT (0.66) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL1667627 | 0.79 | MAPT (0.65) | MAPTCYP1A2CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946031-A | Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors | 北京大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-110384689-A | The purposes of aromatic nitro ethylene compounds | 厦门大学 | 2019-10-29 | — | — | CN | disclosed |
| EP-2872490-B1 | ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES | HOFFMANN LA ROCHE (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9611224-B2 | Antiproliferative benzo [B] azepin-2-ones | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| CN-104507913-A | Antiproliferative benzo[b]azepin-2-ones | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-4061547-A | SUBSTITUTED NAPHTHALENE CARBOXALDEHYDE | COLUMBIA CHEMICAL CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | MAPT 4836/4885CYP1A2 972/4885CYP2C9 2028/4885 |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | CCNY, RB1, TOP2B | MAPT 4882/4885CYP1A2 2008/4885CYP2C9 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.